SAO PAULO (Reuters) - Brazilian health regulator Anvisa on Friday approved clinical trials of a potential coronavirus vaccine developed by China's Sinovac, according to an official gazette publication.
The study - first announced on June 11 - is led by Instituto Butantan, a research center funded by the state of Sao Paulo. The agreement with Sinovac includes not only trials but also the transference of technology to produce the potential vaccine locally.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
